Tag: Health Care

Displaying 541 - 560 of 1002 results.

Pages

Testifying today on behalf of the Federal Trade Commission before the U.S. House Subcommittee on Commerce, Trade, and Consumer Protection of the Committee on Energy and Commerce, FTC Commissioner J. Thomas Rosch said that anticompetitive patent settlements in the U.S. pharmaceutical industry “...
According to the staff of the Federal Trade Commission, legislation pending before the Minnesota legislature that seeks to exempt certain activities by Minnesota health care cooperatives from federal and state antitrust law likely would raise health care costs and reduce insurance coverage for...
Two dietary supplement marketers that lured consumers on the Internet with allegedly deceptive weight-loss claims and bogus “free” sample offers, and then debited their bank accounts or charged their credit cards for continuing shipments without their consent, have agreed to settle Federal Trade...
Commission Approves Final Consent Order in Matter of AllCare IPA – Following a public comment period, the Commission has approved a final consent order in the matter of AllCare IPA. The vote approving the final order was 4-0. (FTC File No. 061-0258; the staff contact is John P. Wiegand, FTC...
The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to Solvay’s branded testosterone-...
Getinge AB has settled Federal Trade Commission charges that its proposed $865 million acquisition of rival Datascope Corporation would be anticompetitive and would violate federal antitrust laws. Under the settlement with the Commission, Datascope is required to divest its endoscopic vessel...
The Commission challenged Getinge AB’s proposed $865 million acquisition of rival Datascope Corporation as anticompetitive in the market for endoscopic vessel harvesting devices (EVHs). EVHs are used during coronary artery bypass graft surgery where a vein is removed from a patients...
The Federal Trade Commission has issued a consent order to settle its charges that King Pharmaceuticals, Inc.’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. would be anticompetitive and would violate federal law. The proposed consent order requires King to divest the rights...
In late 2008, the Commission issued a consent order to restore competition in the market for oral long-acting opioids (LAOs). The FTC intervened in King Pharmaceutical’s proposed $1.6 billion acquisition of rival drug-maker Alpharma Inc. because the transaction would have joined the...
The Commission challenged the conduct of Boulder Valley Individual Practice Association for refusing to deal, or threatening to refuse to deal with insurance providers that failed to increase fees paid to group doctors, and also prevented members from contracting with payers, except...
Physician groups in Modesto, California, and in Boulder County, Colorado, have agreed to settle separate Federal Trade Commission charges that they each violated federal laws. Both groups are charged with orchestrating and carrying out agreements among their members to refuse, and threaten to...
The Commission challenged the conduct of AllCare IPA, alleging that AllCare restrained competition in fee-for-service contracts by fixing prices and other contract terms with payers, engaging in collective negotiations over the terms and conditions of dealing with payers, and...
In order to restore competition in the U.S. market for consumer pregnancy tests, the Commission effectively reversed a consummated transaction in which Inverness Medical Innovations, a 70% market share holder, purchased the assets related to the development of a water-soluble dye...
Teva Pharmaceuticals Industries Ltd.’s has settled Federal Trade Commission charges that its proposed $8.9 billion acquisition of rival generic drugmaker Barr Pharmaceuticals Inc. would be anticompetitive and violate federal law. The consent order requires Teva and Barr to sell assets in 29 U.S....
The Federal Trade Commission today filed a complaint in federal district court challenging Ovation Pharmaceuticals, Inc.’s January 2006 acquisition of the drug NeoProfen, which eliminated its only competitor for the treatment of a serious and potentially deadly congenital heart defect affecting...
In 2006, Ovation Pharmaceuticals, manufacturer of Indocin, a drug used in the treatment of patent ductus arteriosus, a congenital heart defect usually found in severely underweight premature babies, purchased the rights to the drug NeoProfen, a drug about to receive FDA approval for...
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologic Drugs: Framework for Competition and Continued Innovation.” The roundtable will be held in Room 432 at FTC Headquarters in Washington, DC, on November 21, 2008. FTC Commissioner Pamela...
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications...
Following a public comment period, the Commission has approved a final consent order in the matter concerning Fresenius Medical Care AG & Co. KGaA/Daiichi Sankyo Company, Ltd. The vote approving the final order was 4-0. (FTC File No. 081-0146; the staff contact is Elizabeth A. Jex, Bureau of...
Commission approval of public comment period extension – The Commission has approved the publication of a Federal Register notice extending the pubic comment period related to the current regulatory review of the Used Motor Vehicle Trade Regulation Rule (Used Car Rule) through November 19, 2008....

Pages